Successful Treatment of the Anemia of Rheumatoid Arthritis with Subcutaneously Administered Recombinant Human Erythropoietin: Slower response in patients with more severe inflammation

References

• Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966; 3: 351–75
   PubMedGoogle Scholar
• Schilling RF. Anemia of chronic disease. A misnomer. Ann Intern Med 1991; 115: 572–3
   PubMed Web of Science ®Google Scholar
• Baer A N, Dessypris E N, Krdntz SB. The pathogenesis of anemia in rheumatoid arthritis. A clinical and laboratory analysis. Semin Arthritis Rheum 1990; 19: 209–23
   PubMedGoogle Scholar
• Vreugdenhil G, Swaak A JG. Anaemia in rheumatoid arthritis: Pathogenesis, diagnosis and treatment. Rheumatol Int 1990; 9: 243–57
   PubMed Web of Science ®Google Scholar
• Eastgate J A, Symons J A, Wood N C, Grinlinton F M, diGiovine F S, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2: 706–9
   PubMed Web of Science ®Google Scholar
• Schooley J C, Kullgren B, Allison AC. Inhibition by interleukin-1 on the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 1987; 67: 11–7
   PubMed Web of Science ®Google Scholar
• Maury C PJ, Andersson L C, Teppo A-M, Partanen S, Ju-Vonen E. Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1 beta concentrations in anaemic patients and of interleukin 1 mediated suppression of normal crythropoicsis and proliferation of human erythroleukaemia (HEL) cells in vitro. Ann Rheum Dis 1988; 47: 972–8
   PubMed Web of Science ®Google Scholar
• Roodman G D, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of crythrciid progenitors CFU-E and BFU-E and the heniatopoictic ccll lines K 562. HL60 and HEL cells. Exp Hcmatol 1987; 15: 928–35
   PubMed Web of Science ®Google Scholar
• Means RT, Jr, Krantz SB. Inhibition of human crythroid forming units by gamma interferon can bc corrected by recombinant human crythropoietin. Blood 1991; 78: 2564–7
   PubMed Web of Science ®Google Scholar
• Baer A N, Dessypris E N, Goldwasser E, Krantz SB. Blunted erythropoictin response to anaemia in rhcumatoid arthritis. Br J Haematol 1987; 66: 559–64
   PubMed Web of Science ®Google Scholar
• Birgcgård G, Hällgren R, Caro J. Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: relationship to anaemia and the effect of anti-intlammatory treatment. Br J Haematol 1987; 65: 479–83
   PubMedGoogle Scholar
• Means RT, Jr, Olsen N J, Krantz S B, et al. Treatment of the anemia of rheumatoid arthritis with recornbinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 1989; 32: 638–42
   PubMed Web of Science ®Google Scholar
• Pincus T, Olsen N J, Russell J, et al. Multicenter study of recombinant human erythropoietin in the correction of anemia in rheumatoid arthritis. Am J Med 1990; 89: 161–8
   PubMed Web of Science ®Google Scholar
• Takashina N, Kondo H, Kashiwazaki S. Suppressed serum erythropoietin response to anemia and the efficacy of rccombinant erythropoietin in the anemia of rheumatoid arthritis. J Rheumatol 1990; 17: 885–7
   PubMedGoogle Scholar
• Salvarani C, Lasagni D, Casali B, et al. Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease. J Rheumatol 1991; 18: 1168–71
   PubMedGoogle Scholar
• Gudbjörnsson B, Hällgren R, Wide L, Birgegård G. Response of anaemia in rheumatoid arthritis to subcutaneous crythropoietin. Ann Rheum Dis 1992; 51: 717–52
   PubMedGoogle Scholar
• Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Steinbrocker O, Traeger C H, Batterrnan RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659–64
   PubMed Web of Science ®Google Scholar
• Thompson P W, Silman A J, Kirwan JR., Currey HLF. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute phase response. Arthritis Rheum 1987; 30: 618–23
   PubMed Web of Science ®Google Scholar
• Fyhrquist F, Karppinen K, Honkanen T, Saijonmxi O., Rosenlöf K. High serum erythropoietin lcvcls are normalized during treatment of congestive heart failure with enalapril. J Int Med 1989; 226: 257–60
   PubMed Web of Science ®Google Scholar
• Maury C PJ, Teppo A-M, Wegelius O. Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 1982; 41: 268–71
   PubMed Web of Science ®Google Scholar
• Johnson C S, Cook C A, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO). Exp Hematol 1990; 18: 109–13
   PubMed Web of Science ®Google Scholar
• Faquin W, Schneider T J, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987–94
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Nieuwenhuizen C, Feelders R., Van Eijk HG, Swaak AJG. Iron repletion as a contribution to erythropoietin treatment of anaemia in rheumatoid orthritis. Am J Med 1991; 50: 662–3
   Google Scholar